Document is current
Any future updates will be listed below
-
Authors
Göteson, Andreas https://orcid.org/0000-0001-6118-6054
Isgren, Anniella
Jonsson, Lina
Sparding, Timea
Smedler, Erik
Pelanis, Aurimantas
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Jakobsson, Joel
Pålsson, Erik
Holmén-Larsson, Jessica
Landén, Mikael https://orcid.org/0000-0002-4496-6451
-
Funding
Funding for this research was provided by:
Stiftelsen för Strategisk Forskning (KF10-0039)
Vetenskapsrådet (2018-02653)
Hjärnfonden (FO2020-0261)
Grants from the Swedish state under the agreement between the Swedish government and the country councils, the ALF agreement
- License Information
-
More Information
Article History
Received: 22 December 2020
Revised: 8 July 2021
Accepted: 12 July 2021
First Online: 4 August 2021
Competing interests
: ML declares that he has received lecture honoraria from Lundbeck pharmaceutical. JJ declares that he was an employee at AstraZeneca pharmaceutical 2017-2019, and JHL declares that she is a current employee at AstraZeneca pharmaceutical. HZ has served at scientific advisory boards for Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, and CogRx, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. Other authors declare no conflict of interest.
